Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
Executive Summary
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
You may also be interested in...
Fewer US Market Access Restrictions For Branded I&I Drugs Will Drive Growth
Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.
Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis
The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.
Need a specific report? 1000+ reports available
Buy Reports